Literature DB >> 15774493

Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease.

Ariel Diaz1, Martial G Bourassa, Marie-Claude Guertin, Jean-Claude Tardif.   

Abstract

AIMS: Heart rate reduction is the cornerstone of the treatment of angina. The purpose of this study was to explore the prognostic value of heart rate in patients with stable coronary artery disease (CAD). METHODS AND
RESULTS: We assessed the relationship between resting heart rate at baseline and cardiovascular mortality/morbidity, while adjusting for risk factors. A total of 24 913 patients with suspected or proven CAD from the Coronary Artery Surgery Study registry were studied for a median follow-up of 14.7 years. All-cause and cardiovascular mortality and cardiovascular rehospitalizations were increased with increasing heart rate (P<0.0001). Patients with resting heart rate > or =83 bpm at baseline had a significantly higher risk for total mortality [hazard ratio (HR)=1.32, CI 1.19-1.47, P<0.0001] and cardiovascular mortality (HR=1.31, CI 1.15-1.48, P<0.0001) after adjustment for multiple clinical variables when compared with the reference group. When comparing patients with heart rates between 77-82 and > or =83 bpm with patients with a heart rate < or =62 bpm, the HR values for time to first cardiovascular rehospitalization were 1.11 and 1.14, respectively (P<0.001 for both).
CONCLUSION: Resting heart rate is a simple measurement with prognostic implications. High resting heart rate is a predictor for total and cardiovascular mortality independent of other risk factors in patients with CAD.

Entities:  

Mesh:

Year:  2005        PMID: 15774493     DOI: 10.1093/eurheartj/ehi190

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  182 in total

Review 1.  Heart rate: a forgotten link in coronary artery disease?

Authors:  Kim M Fox; Roberto Ferrari
Journal:  Nat Rev Cardiol       Date:  2011-04-26       Impact factor: 32.419

Review 2.  Advancements in pharmacotherapy for angina.

Authors:  Ankur Jain; Islam Y Elgendy; Mohammad Al-Ani; Nayan Agarwal; Carl J Pepine
Journal:  Expert Opin Pharmacother       Date:  2017-03-15       Impact factor: 3.889

Review 3.  Is heart rate a treatment target in heart failure?

Authors:  Jan-Christian Reil; Michael Böhm
Journal:  Curr Cardiol Rep       Date:  2012-06       Impact factor: 2.931

Review 4.  Role of heart rate as a marker and mediator of poor outcome for patients with heart failure.

Authors:  John R Kapoor; Paul A Heidenreich
Journal:  Curr Heart Fail Rep       Date:  2012-06

5.  Assessing left ventricular systolic dysfunction after myocardial infarction: are ejection fraction and dP/dt(max) complementary or redundant?

Authors:  Kiyotake Ishikawa; Elie R Chemaly; Lisa Tilemann; Kenneth Fish; Dennis Ladage; Jaime Aguero; Torsten Vahl; Carlos Santos-Gallego; Yoshiaki Kawase; Roger J Hajjar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-02-03       Impact factor: 4.733

6.  Heart rate and outcome in heart failure with reduced ejection fraction: Differences between atrial fibrillation and sinus rhythm-A CIBIS II analysis.

Authors:  Bart A Mulder; Kevin Damman; Dirk J Van Veldhuisen; Isabelle C Van Gelder; Michiel Rienstra
Journal:  Clin Cardiol       Date:  2017-05-17       Impact factor: 2.882

Review 7.  Perspectives of I(f) inhibition by ivabradine in cardiology.

Authors:  Michael Böhm; Jan-Christian Reil
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 8.  The funny current: cellular basis for the control of heart rate.

Authors:  Dario DiFrancesco; Jeffrey S Borer
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 9.  Heart rate as an independent risk factor for cardiovascular disease: current evidence and basic mechanisms.

Authors:  Paolo Palatini
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 10.  Clinical results of I(f) current inhibition by ivabradine.

Authors:  Jean-Claude Tardif
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.